Clinical trials: Biotherapy
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients.
- Trial name
- ABI-RA (NCT02116504)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Inflammatory Rhinitis
"Clinical and Epidemiological Characteristics of Inflammatory Rhinitis in Patients on Biotherapies"
Inflammatory rhinitis is a side effect observed in patients treated with biotherapies in the context of chronic bowel disease (IBD) or spondylartrhopathy (SPA). This damage is still poorly described in the literature.
- Trial name
- RIB18 (NCT04132258)
- Testing
- survey
- Where
- France
- Volunteers
- 356 people
- Sponsor
- Nantes University Hospital
Crohn's Disease
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in adults with moderately and severely active Crohn's disease (CD).
- Trial name
- U-EXCEL (NCT03345849)
- Testing
- Upadacitinib
- Where
- 432 sites in United States, Argentina and 47 more
- Volunteers
- 526 people
- Sponsor
- AbbVie
Leukemia
Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia
RATIONALE: Biological therapy may increase the number of immune cells found in bone marrow and may help a person's immune system recover from the side effects of the chemotherapy used in treating chronic myeloid leukemia.
- Trial name
- NCT00011934
- Testing
- recombinant interferon alfa, sargramostim, autologous bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma (Skin)
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and…
- Trial name
- NCT00006113
- Testing
- MART-1 antigen, aldesleukin, gp100 antigen
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Southern California
Sarcoma
Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00003667
- Testing
- cyclophosphamide, dexrazoxane hydrochloride, disaccharide tripeptide glycerol dipalmitoyl
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ankylosing Spondylitis
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
The goal of this research is to assess the percentage of non-responders to ≥ 2 NSAIDs candidates a biological therapy that could adequately respond to treatment with etoricoxib This study confirm the result of a previous study in…
- Trial name
- NCT01091675
- Testing
- Etoricoxib
- Where
- 14 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Spanish Foundation of Rheumatology
Immunologic and Inflammatory Diseases
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Infections represent the first cause of death and of morbidity in people treated for immunologic and inflammatory diseases with corticosteroids, immunosuppressive drugs or biotherapy.
- Trial name
- INFIM (NCT02280902)
- Testing
- Blood samples
- Where
- 7 sites in France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Bordeaux
Bacterial Pneumonia
Cx611-0204 SEPCELL Study
The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered intravenously as adjunctive therapy, therefore in…
- Trial name
- SEPCELL (NCT03158727)
- Testing
- Cx611
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 84 people
- Sponsor
- Tigenix S.A.U.
Colorectal Cancer, Colon Cancer
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) and Aldesleukin (interleukin-2, IL-2) immunotherapy in patients with…
- Conditions
- Colorectal Cancer, Colon Cancer, Rectum Cancer
- Trial name
- BAH248 (NCT06530303)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Axial Spondyloarthrithis, Inflammatory Diseases
EXercise Therapy in Axial SpA, Inflammation and Biologic Therapy (ExTASI-B)
The goal of this randomised controlled trial study is to investigate whether exercise (brisk walking, equal to 13 on a rating of perceived exertion scale; somewhat hard) can be used as an adjuvant therapy for people living with…
- Conditions
- Axial Spondyloarthrithis, Inflammatory Diseases, Arthritis
- Trial name
- ExTASI-B (NCT06669702)
- Testing
- 12-week home based exercise, Routine care
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Multiple Myeloma and Plasma Cell Neoplasm
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with multiple myeloma that has recurred following bone marrow transplantation.
- Trial name
- NCT00003153
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma
MUK Nine b: OPTIMUM Treatment Protocol
To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab (Darzalex) \& dexamethasone in combination with low-dose cyclophosphamide is sufficiently active in a high risk…
- Trial name
- MUKnineb (NCT03188172)
- Testing
- Cyclophosphamide, Bortezomib, Lenalidomide
- Where
- 21 sites in United Kingdom
- Volunteers
- 95 people
- Sponsor
- University of Leeds
Inflammatory Bowel Disease, Crohn Disease
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
- Trial name
- NCT04331639
- Testing
- vitamin D3
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Boston Children's Hospital
Brain and Central Nervous System Tumors
Biological Therapy in Treating Patients With Primary or Advanced Glioma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells in patients with primary or…
- Trial name
- NCT00003067
- Testing
- aldesleukin, lymphokine-activated killer cells
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Melanoma (Skin)
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as sargramostim and interferon alfa use different ways to stimulate the immune system and stop cancer cells from…
- Trial name
- NCT00006385
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- 32 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Psoriasis
Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis
PSOBIOTEQ is a national multicentric prospective cohort of cutaneous psoriasis patients receiving systemic treatment (biotherapy or DMARDs) for moderate to severe cutaneous psoriasis.
- Trial name
- PSOBIOTEQ (NCT01617018)
- Where
- France
- Volunteers
- 4,613 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation or bone marrow transplantation may allow the…
- Trial name
- NCT00008203
- Testing
- aldesleukin, recombinant interferon gamma, carboplatin
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Ovarian Cancer
Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
The goal of this clinical research study is to find the highest safe dose of intraperitoneal tgDCC-E1A that can be given in combination with paclitaxel as a treatment for patients with recurrent, platinum-resistant ovarian…
- Trial name
- NCT00102622
- Testing
- Intraperitoneal tgDCC-E1A, Paclitaxel
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Kidney Cancer
Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030342
- Testing
- recombinant interferon alfa, sargramostim, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- St. Luke's Medical Center